TKNO ALPHA TEKNOVA INC

Teknova to Present at 2022 Cell & Gene Meeting on the Mesa

Teknova to Present at 2022 Cell & Gene Meeting on the Mesa

HOLLISTER, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that Stephen Gunstream, President and Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13, 2022, in Carlsbad, California, and livestreamed globally.

The presentation will provide an update on the company’s growth strategy, insights from their Research and Development team, and the latest on their product development efforts supporting the gene therapy category. Specific presentation details are as follows:

 Event:2022 Cell & Gene Meeting on the Mesa
 Date:Wednesday, October 12, 2022
 Time:5:45 p.m. Pacific Time
 Location:Oxford Biomedica Ballroom at the Park Hyatt Aviara Resort, Carlsbad, CA

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference that brings together senior executives and top decision-makers in the industry to highlight key technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

A live broadcast of the presentation will be available for registered participants and will be available on the conference website after the event concludes. In addition, the presentation will be published on the Investor Relations section of once available. For more conference information or to register, visit .



Investor Contacts
Matt Lowell
Chief Financial Officer
 
 

Sara Michelmore
MacDougall Advisors
 
 

Media Contact
Jenn Henry
Senior Vice President, Marketing
 
 
EN
05/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova Reports First Quarter 2025 Financial Results

Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for...

 PRESS RELEASE

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern T...

 PRESS RELEASE

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation...

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, ...

 PRESS RELEASE

Teknova and Pluristyx Announce Collaboration to Streamline the Manufac...

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx’s Novel PluriFreeze™ Cryopreservation System HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic...

 PRESS RELEASE

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue guidance of $39-42 million HOLLISTER, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announce...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch